Executive Series - Opthea (OPT) CEO & Managing Director, Megan Baldwin
CommSec
Online Stockbroker
Tom Piotrowski speaks with Opthea (OPT) CEO & Managing Director, Megan Baldwin about the results of its Phase 2 study of its OPT-302 drug aimed at treating the Wet AMD eye disease
To view more Executive Series interviews, visit: (VIEW LINK)
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful trading tools including alerts, conditional orders, stock screeners and comparison charts.
3 topics
CommSec
Online Stockbroker
Online Stockbroker
CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful...
Expertise
No areas of expertise
CommSec
Online Stockbroker
Online Stockbroker
CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful...
Expertise
No areas of expertise
Comments
Comments
Sign In or Join Free to comment
most popular
Equities
The 7 zombie companies lurking on the ASX 300
Livewire Markets
Education
Warren Buffett’s 25 biggest mistakes – and 4 lessons they teach
Leithner & Company Ltd